Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesProspective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node–negative melanoma
Journal of Clinical Oncology, 07/20/09
Hauschild A et al. – Study reports that the addition of a 4-week modified high-dose IFN-α (HDI) induction phase to a 2-year low-dose adjuvant IFN-α-2b treatment schedule for patients with high-risk melanoma did not improve the clinical outcome.
Methods- Main objectives of this study were to investigate the:
- Optimal dosing and duration of treatment with IFN-α, and
- If HDI, the intravenous (IV) induction phase might be critical for the clinical benefit of the regimen
- Lymph node–negative pts with resected primary malignant melanoma of >1.5-mm tumor thickness were included
- 674 pts randomly assigned to receive 4 wks of a modified HDI scheme
- This schedule consisted of:
- 5 times weekly 10 MU/m2 IFN-α-2b IV for 2 wks, and
- 5 times weekly 10 MU/m2 IFN-α-2b administered sc for another 2 wks, followed by
- 23 mo of low-dose IFN-α-2b (LDI) 3 MU SC 3 times a wk (arm A)
- LDI 3 MU 3 times a week was given for 24 mo in arm B
- Of 650 assessable pts, there were 92/321 relapses among pts receiving high-dose induction vs 95/329 relapses among the pts receiving LDI only
- 5-yr relapse-free survival rates were 68.0% (arm A) and 67.1% (arm B), respectively
- Likewise, melanoma-related fatalities were similar between both groups, resulting in 5-yr overall survival rates of 80.2% (arm A) and 82.9% (arm B)
Related Articles
Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma
Cancer, 10/22/09
Relevance Score: 96%
Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09
Relevance Score: 94%
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial : The Lancet Oncology
The Lancet Oncology - Online First, 10/23/09
Relevance Score: 93%
Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: Results of a large observational study
Annals of Oncology, 10/29/09
Relevance Score: 90%
Risperidone dose for schizophrenia
Cochrane Reviews, 10/22/09
Relevance Score: 90%
Today in Dermatologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Pathology Review of Thin Melanoma and Melanoma in Situ in a Multidisciplinary Melanoma Clinic: Impact on Treatment Decisions
Journal of Clinical Oncology, 12/19/09
Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions
Human Pathology, 12/19/09
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays
Human Pathology, 12/19/09
Sponsor
Article Search
Sponsor
Sponsor